TY - JOUR
T1 - Immunotherapy for early stage colorectal cancer
T2 - A glance into the future
AU - Cohen, Romain
AU - Shi, Qian
AU - André, Thierry
N1 - Funding Information:
Acknowledgments: R.C. reports grants from Nuovo-Soldati foundation, ARC Foundation for cancer research and Servier Institute.
Funding Information:
R.C. reports grants from Nuovo-Soldati foundation, ARC Foundation for cancer research and Servier Institute.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/7
Y1 - 2020/7
N2 - Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR.
AB - Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR.
KW - Immunoscore
KW - Microsatellite instability
KW - Mismatch repair deficiency
KW - Oxaliplatin
KW - Stage III
UR - http://www.scopus.com/inward/record.url?scp=85088160423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088160423&partnerID=8YFLogxK
U2 - 10.3390/cancers12071990
DO - 10.3390/cancers12071990
M3 - Review article
AN - SCOPUS:85088160423
SN - 2072-6694
VL - 12
SP - 1
EP - 14
JO - Cancers
JF - Cancers
IS - 7
M1 - 1990
ER -